Nitric oxide mediated venodilator effects of nebivolol.
- 1 September 1994
- journal article
- clinical trial
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 38 (3) , 199-204
- https://doi.org/10.1111/j.1365-2125.1994.tb04342.x
Abstract
1. Nebivolol, a selective beta 1‐adrenoceptor antagonist with antihypertensive effects, has haemodynamic effects suggestive of a direct vasodilator action. 2. The dorsal hand vein technique was used to determine whether nebivolol has venodilator action in vivo in man. 3. Nebivolol and atenolol were infused into the phenylephrine preconstricted superficial hand veins of 11 healthy male volunteers. In separate studies L‐NMMA (0.1 microgram min‐1) was pre‐ and co‐infused with nebivolol to determine whether nitric oxide (NO) mediated mechanisms were present. Further studies with prostaglandin F2 alpha (PGF2 alpha) preconstriction were performed to exclude an alpha‐ adrenergic antagonistic effect of nebivolol. Effects of L‐NMMA infusion on nitroglycerin venodilation were also determined. 4. Nebivolol produced a dose dependent venodilation, (72 +/‐ 18% maximum), whereas atenolol produced no significant venodilation. At doses of nebivolol producing plasma concentrations comparable with plasma levels achieved after standard oral dosing (10(‐13)‐10(‐12) mol min‐1) small (14 +/‐ 6% and 23 +/‐ 8%) but significant (P < 0.05) venodilation was observed. 5. The venodilator response to nebivolol was significantly reduced by infusion of L‐NMMA (maximum dilation 18% vs 72%, P < 0.01). Venodilator responses to nitroglycerin were unaffected by L‐NMMA infusion. A venodilator effect to nebivolol was also seen following preconstriction with PgF2 alpha (40 +/‐ 20% maximum). 6. Nebivolol has nitric oxide mediated, venodilator effects in man.Keywords
This publication has 26 references indexed in Scilit:
- Beta blockers and the failing heart: is it time for a U-turn?Heart, 1993
- CarvedilolDrugs, 1993
- Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertensionJournal Of Hypertension, 1992
- Measurements of Serum Levels of Nitrate Ions in Men and Women: Implications of Endothelium-Derived Relaxing Factor in Blood Pressure Regulation and AtherosclerosisJournal of Cardiovascular Pharmacology, 1992
- Effects of the Selective β1-Adrenoceptor Antagonist, Nebivolol, on Cardiovascular Parameters in the Pithed Normotensive RatPharmacology, 1990
- Nitric oxide synthesised from L-arginine mediates endothelium dependent dilatation in human veins in vivoCardiovascular Research, 1989
- Nebivolol is devoid of intrinsic sympathomimetic activityEuropean Journal of Pharmacology, 1989
- Pharmacological and Hemodynamic Profile of Nebivolol,* a Chemically Novel, Potent, and Selective β1-Adrenergic AntagonistJournal of Cardiovascular Pharmacology, 1988
- Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factorNature, 1987
- Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5'-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta.Journal of Clinical Investigation, 1987